MELANOMA RESEARCH FOUNDATION (EIN 760514428) - Form 990 Financial Analysis & Trantor Score

🔒

Financial Vulnerability Assessment (Tuckman-Chang)

4 risk indicators measuring financial stability and operational resilience

Sign in with your work email to view Tuckman-Chang indicators

Financial Trends

Organization Details

Formation Year

1996

Legal Domicile

Principal Officer

KYLEIGH LIPIRA

Phone

8006731290

Tax Period

2023-04-01 to 2024-03-31

MELANOMA RESEARCH FOUNDATION, founded in 1996, is a community nonprofit in the Unknown sector that reported $7.8M in total revenue in fiscal year 2023. Revenue grew 18% year-over-year, indicating healthy expansion. Expenses of $6.7M left a modest 14% surplus.

Mission

TO ERADICATE MELANOMA BY ACCELERATING MEDICAL RESEARCH WHILE EDUCATING TO AND ADVOCATING FOR THE MELANOMA COMMUNITY.

🔒

Trantor Score

Financial Health Score (300–850) · Liquidity · Solvency · Sustainability · Efficiency

Sign in to view Trantor Score and financial metrics

Liquidity (40%) • Solvency (30%) • Sustainability (20%) • Efficiency (10%)

Financial Overview (2023)

Revenue Breakdown

Contributions & Grants $8,303,636

Program Service Revenue $0

Investment Income $242,977

Other Revenue $-772,051

TOTAL REVENUE $7,774,562

Expense Breakdown

Grants Paid $1,849,954

Salaries & Benefits $2,112,375

Fundraising Expenses $462,864

Program Expenses $5,460,853

Other Expenses $2,734,890

TOTAL EXPENSES $6,697,219

Year-over-Year Comparison

	2023	2022	Change
Revenue	$7,774,562	$6,578,223	+0.2%
Expenses	$6,697,219	$6,478,760	+0.0%
Net Income	$1,077,343	$99,463	+9.8%

Key Indicators

✓ Grants to Organizations ✓ Grants to Individuals ✓ Lobbying ✗ Political Activity ✗ Foreign Activities ✗ Donor Advised Fund ✓ Schedule B Required

🔒

Financial Health Indicators

Comprehensive financial analysis: Altman Z-Score, liquidity, solvency, sustainability, efficiency, and growth metrics

Financial Distress Indicator

Liquidity & Cash Position

Sign in to view all financial metrics

Altman Z-Score • Liquidity Ratios • Solvency Analysis • Growth Indicators • Efficiency Metrics

Governance

Voting Members

Independent Members

Employees

Volunteers

295

Governance Policies

✓ Conflict of Interest Policy

✓ Whistleblower Policy

✓ Document Retention Policy

Special Practices & Reported Activities

✗ Operated a School

✗ Operated a Hospital

✗ Provided First Class Travel

✗ Reported Conflict of Interest

✗ Reported Asset Diversion

✗ Excess Benefit Transaction

✗ Made Political Expenditures

✓ Engaged in Lobbying

✗ Operated Donor Advised Fund

✗ Maintained Art Collections

✗ Filed Form 720

Compensation of Officers, Directors & Key Employees

Total Officers

$347,681

Total Directors

$347,681

Key Employees

Highest Compensated

reported

Name	Title	Hours/Week	Role	Reportable Comp	Other Comp	Total
KYLEIGH LIPIRA	CEO	40.00	Officer Director	$336,485	$11,196	$347,681
JAMES MERRICK	CHIEF COMMUNICATIONS OFFICER	40.00	Highest	$178,462	$8,755	$187,217
JESSICA ALLISON	DIRECTOR OF CORPORATE RELATIONS	40.00	Highest	$114,686	$10,907	$125,593
DOUGLAS BRODMAN	CHAIR	2.00	Officer Director	$0	$0	$0
ALISON MARTIN MD	VICE CHAIR - UNTIL 01/2024	2.00	Officer Director	$0	$0	$0
THOMAS WESTDYK SECRETARY	AND GOVERNANCE - AS OF 01/2024	2.00	Officer Director	$0	$0	$0
CHERUL STRATOS	SECRETARY - UNTIL 12/2023	2.00	Officer Director	$0	$0	$0
JILL WROBEL	TREASURER	2.00	Officer Director	$0	$0	$0
STAN ADLER	BOARD MEMBER	1.00	Director	$0	$0	$0
MICHAEL B ATKINS MD	SAC CO-CHAIR	1.00	Director	$0	$0	$0
ELISE BARISH	BOARD MEMBER	1.00	Director	$0	$0	$0
KRISTINA BAUM	BOARD MEMBER	1.00	Director	$0	$0	$0
LAURA FERRIS MD	BOARD MEMBER	1.00	Director	$0	$0	$0
GLENN MERLINO	SAC CO-CHAIR - UNTIL 12/2023	1.00	Director	$0	$0	$0
GIULIA NEWTON	BOARD MEMBER	1.00	Director	$0	$0	$0
ASHANI WEERARATNA MD	SAC CO-CHAIR	1.00	Director	$0	$0	$0

Note: Compensation data is self-reported by the organization on their Form 990. "Reportable Comp" includes salary, bonuses, and other reportable compensation from the organization and related organizations. "Other Comp" includes benefits, deferred compensation, and non-taxable benefits.

Historical Data

Year	Revenue	Expenses	Assets	Net Income
2025	No data	No data	No data	No data
2024	$7,774,562	$6,697,219	$7,270,872	$1,077,343
2023	$6,578,223	$6,478,760	$6,173,374	$99,463
2022	$6,918,058	$5,575,310	$5,064,088	$1,342,748
2021	$5,128,245	$4,808,451	$4,048,990	$319,794
2020	$5,640,236	$5,203,544	$2,657,969	$436,692
2019	$5,352,231	$4,807,267	$1,963,873	$544,964

MELANOMA RESEARCH FOUNDATION